Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MTTP | P55157 | 10/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.31 |
| ▸ | APOB | P04114 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.30 |
| ▸ | MICA | Q29983 | 2/20 | 0.30 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031658 | 0.96 | NTRK1 (0.35) | NTRK1MTTPAPOBPOLQKCNH2 | |
| SCHEMBL5064935 | 0.95 | MTTP (0.35) | NTRK1MTTPKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5064926 | 0.93 | MTTP (0.38) | NTRK1MTTPAPOBKLRK1MICA | |
| SCHEMBL5066053 | 0.93 | MTTP (0.33) | NTRK1MTTPPOLQ | |
| SCHEMBL14031586 | 0.92 | NTRK1 (0.32) | NTRK1MTTPKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5065880 | 0.90 | MTTP (0.32) | MTTP | |
| SCHEMBL5064968 | 0.89 | MTTP (0.34) | MTTPKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL5065981 | 0.89 | MTTP (0.31) | NTRK1MTTPKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5065965 | 0.89 | NTRK1 (0.40) | NTRK1 | |
| SCHEMBL5065024 | 0.88 | MTTP (0.39) | MTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | claimed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060205726-A1 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205726-A1 | Ester derivatives and medical use thereof | MTTP, LIPC, CETP | NTRK1 4115/4885MTTP 1/4885KCNQ3 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.